ClinVar Miner

Submissions for variant NM_000162.5(GCK):c.1310C>T (p.Thr437Ile)

dbSNP: rs1185622190
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen Monogenic Diabetes Variant Curation Expert Panel RCV003493719 SCV004242353 likely pathogenic Monogenic diabetes 2024-01-28 reviewed by expert panel curation The c.1310C>T variant in the glucokinase gene, GCK, causes an amino acid change of threonine to isoleucine at codon 437 (p.(Thr437Ile)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is also predicted to be deleterious by computational evidence, with a REVEL score of 0.7269, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent from gnomAD v2.1.1 (PM2_Supporting), and was identified in 4 unrelated individuals with hyperglycemia; (PS4_Moderate; ClinVar ID 585914, PMID 28323911, internal lab contributors). Two of these individuals had a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and documented persistent impaired fasting glucose or negative antibodies) (PP4_Moderate; PMID: 28323911, internal lab contributors). In summary, c.1310C>T meets the criteria to be classified as likely pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PS4_Moderate, PP2, PP3, PM2_Supporting, PP4_Moderate.
Athena Diagnostics Inc RCV000711765 SCV000842159 uncertain significance not provided 2018-06-07 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV000764717 SCV000895851 uncertain significance Permanent neonatal diabetes mellitus; Type 2 diabetes mellitus; Hyperinsulinism due to glucokinase deficiency; Maturity-onset diabetes of the young type 2 2018-10-31 criteria provided, single submitter clinical testing
Invitae RCV000711765 SCV004295122 uncertain significance not provided 2023-04-26 criteria provided, single submitter clinical testing Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GCK protein function. ClinVar contains an entry for this variant (Variation ID: 585914). This missense change has been observed in individual(s) with maturity onset diabetes of the young (PMID: 28323911). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces threonine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 437 of the GCK protein (p.Thr437Ile). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.